

FEBRUARY
3-7, 2018



Pierre Baudis
Congress Center
Toulouse - France

A UNIQUE INTERNATIONAL EVENT,
PART OF THE WORLD CANCER DAY 2018

BE
PART
OF IT!

PROGRAMME

2nd edition of the international scientific symposium

EXHIBITION AREA | ONE TO ONE MEETINGS | COMPANY/TECHNOLOGY PRESENTATIONS | PUBLIC SESSION



CONTENTS

EDITO	3
COMMITTEES	4
PROJECT HOLDERS	8
INVITED SPEAKERS	10
SCIENTIFIC PROGRAM	
GENERAL PROGRAM	22
DETAILED SESSIONS	24
POSTERS	30
PITCHES	36
PUBLIC CONFERENCE	44
MEDICAL SESSION	45
INSTITUTIONAL PARTNERS	46

EDITO



Prof André Syrota,

President of the Institut Universitaire du Cancer de Toulouse

The Toulouse Onco Week will showcase the best cancer science and medicine from internationally renowned scientists around the world. They will present an overview of state-of-the-art basic and translational cancer research, exploring the latest discoveries in cancer dissemination, cancer cell metabolism, genetic instability, epigenetics, non-coding genome in cell transformation, targeted therapies and drug resistance, cancer immunology and radiotherapy. This symposium will appeal to a broad spectrum of basic and clinical scientists and will gather junior and senior researchers around original communications.

In parallel, meetings with pharmaceutical companies will reinforce scientist and company interactions. The TOW will be also a unique opportunity to disseminate novel trends in oncology at a general public session and to participate to charity events. Be part of this unique event in Toulouse.



Mr Jean-Luc Moudenc,

Mayor of Toulouse ; President of Toulouse Metropole

By bringing together scientific, clinical and economic expertise to accelerate research and discovery of personalised therapeutic applications, the Oncopole epitomises Toulouse's commitment to innovation in the life sciences.

The organization of Toulouse Oncoweeek 2018 will be the opportunity for the researchers, clinicians, and biotechs to have high-level scientific exchanges in a city which places the excellence and the innovation at the heart of its action.

COMMITTEES

Scientific Committee

Michel ATTAL, MD, PhD

- General Director of Institut Universitaire du Cancer de Toulouse (IUCT)-Oncopole

Christine BEZOMBES, PhD

- Senior scientist, «Therapeutic Innovations in B lymphomas» team Centre de Recherches en Cancérologie de Toulouse (CRCT)

Pierre BROUSSET, MD, PhD

- Head of Laboratoire d'Anatomie Cytologie Pathologiques Institut Universitaire du Cancer de Toulouse (IUCT)-Oncopole
- Head of «RNA biology in hematological cancers» team Centre de Recherches en Cancérologie de Toulouse (CRCT)

Louis CASTEILLA, PhD

- Director of STROMALab

**Elizabeth COHEN-JONATHAN
MOYAL**, MD, PhD

- Head of Radiation Oncology Department Institut Universitaire du Cancer de Toulouse (IUCT)-Oncopole
- Head of «Glioblastoma radioresistance : from signalling pathways to clinical trials» team Centre de Recherches en Cancérologie de Toulouse (CRCT)

Jean-Pierre DELORD, MD, PhD

- Director of Bureau d'études cliniques (BEC)
- Head of Medical Oncology Department Institut Universitaire du Cancer de Toulouse (IUCT)-Oncopole
- Member of «SIGDYN Group - PI3K isoforms, Signalling & Cancerogenesis» team Centre de Recherches en Cancérologie de Toulouse (CRCT)

Bernard DUCOMMUN, MD, PhD

- Director of ITAV – Centre Pierre Potier

Gilles FAVRE, Pharm D, PhD

- Director of Centre de Recherches en Cancérologie de Toulouse (CRCT) Head of «Cancer cell signaling and therapeutics» team
- Scientific Director & Head of the Medical Biology Department Institut Universitaire du Cancer de Toulouse (IUCT)–Oncopole
- Director of Cancéropole Grand Sud-Ouest

Jean-Philippe GIRARD, PhD

- Director of Institut de Pharmacologie et de Biologie Structurale (IPBS)
Head of «Vascular biology: Endothelial cells, inflammation and cancer» team

Julie GUILLERMET-GUIBERT,
PhD

- Head of «SIGDYN Group - PI3K isoforms, Signalling & Cancerogenesis» team
Centre de Recherches en Cancérologie de Toulouse (CRCT)

Julien MAZIERES, MD, PhD,

- Pulmonologist and Oncologist, Institut Universitaire du Cancer de Toulouse
Rangueil-Larrey
- Member of «Cancer cell signaling and therapeutics» team
Centre de Recherches en Cancérologie de Toulouse (CRCT)

Mary POUPOT, PhD

- Senior scientist, «Therapeutics Innovations in B lymphomas» team
Centre de Recherches en Cancérologie de Toulouse (CRCT)

Christian RECHER, MD, PhD

- Head of Hematology Department
Institut Universitaire du Cancer de Toulouse (IUCT)-Oncopole
- Member of «RESIST@ML - Drug resistance and oncometabolism in acute
myeloid leukemia» team
Centre de Recherches en Cancérologie de Toulouse (CRCT)

Henri ROCHÉ, MD, PhD

- Head of Medical Affairs Department
- Head of Breast cancer Department
Institut Universitaire du Cancer de Toulouse (IUCT)-Oncopole

Didier TROUCHE, PhD

- Director of Center for Integrative Biology (CIB)
- Director of «Laboratoire de biologie cellulaire et moléculaire du contrôle
de la prolifération» (LBCMCP)
Head of «Chromatin and cell proliferation» team

Organizing Committee

Christine BEZOMBES, PhD

- Senior scientist, «Therapeutic Innovations in B lymphomas» team
Centre de Recherches en Cancérologie de Toulouse (CRCT)

Benjamin GANDOUET

- Director Oncopole-Sciences du Vivant et Santé Publique
DGD – Gouvernance, International, Economie et Emploi
Toulouse Métropole

Lionel HAVION

- Scientific Partnership Manager
Fondation Toulouse Cancer Santé
#cancerousconcernés

François LAFONT

- Development Director, So TOULOUSE CONVENTION BUREAU
• ESOF 2018 Project Manager / EuroScience Open Forum
Université Fédérale Toulouse Midi-Pyrénées

Dominique LAUTIER, PhD

- Scientific Partnership Manager
Centre de Recherches en Cancérologie de Toulouse (CRCT)

Marie-Ange LEOPHONTE

- Director of Ligue Contre le Cancer 31

Alexis MONNIER

- General Director of Cancer Bio-Santé Competitiveness Cluster

Mary POUPOT, PhD

- Senior scientist, «Therapeutics Innovations in B lymphomas» team
Centre de Recherches en Cancérologie de Toulouse (CRCT)

Marion SALVADOR

- Oncology Business Development
Cancer Bio-Santé Competitiveness cluster

Fabienne de TONI-COSTES,
PhD

- Project Manager Biotechnologies and Oncology
Cancer Bio-Santé Competitiveness Cluster

PROJECT HOLDERS

Institut Universitaire du Cancer de Toulouse



A campus dedicated to cancer care and innovative strategies in health. For the first time in Europe, the Oncopole of Toulouse, gathers researchers, academic and private laboratories, industries, startup, medical care center focusing on research and discovering innovative and individualized treatments. The power of Oncopole is the gathering of talents, projects and platforms strengthening Toulouse commitment in scientific innovation dedicated to research and care. With a 1 billion euro investment, more than 1500 researchers, 1400 medical actors and more than 300,000 m² of new buildings, Oncopole makes fundamental and clinical sciences, medical and human sciences, companies of health and innovation converge on an exceptional site of 220 hectares.

Contact : Valérie Flipo

Cancer Research Center of Toulouse



The CRCT is a public research institute affiliated as UMR1037 (Mixed unit) of Inserm, University Toulouse III-Paul Sabatier and ERL5294 by CNRS. It is now composed of 20 research teams, services and facilities. The institute is located on the "Oncopole" campus where academic, scientific, medical, clinical, technological and pharmaceutical researchers are interacting together. With 450 people working as researchers, students, clinicians, technical or administrative staff, the CRCT allows in accordance to Inserm objectives, a research from the bench to bed of patients.

Contacts : Mary Poupot & Christine Bezombes

Toulouse Métropole



Together against Cancer: «eradicate the disease, surround the patient».

As a leader in the development of the campus, Toulouse Métropole supports all the actors of the care, the public and private research, and the economic and social world, to make Oncopole an international showcase of scientific excellence territory.

Contact : Benjamin Gandouet

Cancer-Bio-Santé



Cancer-Bio-Santé (CBS) is a cluster dedicated to innovation in the field of cancer. Since the end of 2013, the cluster is also working on the monitoring and the following of ageing people. The cluster was created to provide support for more than 200 companies in the Midi-Pyrénées and Limousin Regions, working in collaboration with research laboratories, cancer centers and hospitals, to develop innovative products for cancer treatment and care and place them on the international market. In addition, the CBS Cluster targets a multidisciplinary approach and operates throughout the value chain covering the landscape of cancer and ageing, from prevention to follow up and home care including e-health technologies.

Contact : Alexis Monnier

La Ligue contre le cancer



1st French NGO private & nonprofit funder for research against cancer.

The Ligue contre le cancer finances the best research teams ensuring considerable advances in treatment. Financing more than 800 research projects yearly in France, the Ligue has invested 400 M€ in the past decade in research against cancer.

Other missions of the Ligue contre le cancer missions:

- **Prevent to protect:** the Ligue contre le cancer encourages early detection and prevention to reduce the risk of cancer.
- **Support to help:** the Ligue contre le cancer informs and helps patients during and after the disease.
- **Defending equal rights in healthcare:** The Ligue contre le cancer approved to represent the users of the French healthcare system: 500 representatives defend the rights of the patients and their relatives. The Ligue contre le cancer, a non-political NGO relying on the commitment of its volunteers & the generosity of the public.

Contact : Marie-Ange Leophonte

Fondation Toulouse Cancer Santé #CancerTousConcernés



The Fondation Toulouse Cancer Santé is a private «nonprofit» foundation created by Amgen, GlaxoSmithKline, Pierre Fabre, Siemens, and Total with the participation of the French National Research Agency (ANR). The specific aim of the Foundation is to promote the Toulouse - Oncopole University Institute of Cancer, by selecting public and private research partnerships and financing:

- interdisciplinary research in the technologies domain and in life sciences in general, applied in diagnostics and drug discovery, with a special focus in oncology.
- technological platforms dedicated to the whole regional scientific community.

Thanks to the support of numerous companies and private donors, Toulouse Cancer Santé is funding several innovative projects in the regional research centers.

Contact: Lionel Havion

Agence d'Attractivité Toulouse



Agence d'Attractivité Toulouse - Tourisme - meetings - business capitalizes the expertise of three sectors: tourism, meetings and economic development. Its missions:

- To develop Toulouse notoriety and international image.
- Encourage tourist attendance through the direct incoming or intermediation.
- Prospecting high added-value industrial projects.
- Welcome and ensure the engineering of any exogenous project, creator of jobs and wealth.
- Create good conditions for the meeting industry development (prospecting and hosting international congresses with a strong scientific content).

INVITED SPEAKERS

SESSION 1 - Metastasis & microenvironment - Metabolism




Klaus Pantel (University Medical Center Hamburg-Eppendorf)

Prof Pantel is Chairman of the Institute of Tumour Biology at the University Medical Center Hamburg- Eppendorf. The institute is part of the Centre of Experimental Medicine and the University Cancer Center Hamburg (UCCH). The pioneer work of Prof Pantel in the field of cancer micrometastasis, circulating tumor cells and circulating nucleic acids (ctDNA, microRNAs) is reflected by more than 400 publications in excellent high ranking biomedical and scientific journals (incl. NEJM, Lancet, Nature Journals, Cancer Cell, Science Translational Medicine, Cancer Discovery, PNAS, JCO, JNCI, Cancer Res.) and has been awarded the AACR Outstanding Investigator Award 2010, German Cancer Award 2010, and ERC Advanced Investigator Grant 2011. Moreover, Prof Pantel coordinates the European TRANSCAN group “CTC-SCAN”, the European IMI consortium CANCER-ID (www.cancer-id.eu) on blood-based “Liquid Biopsies” and serves on the Editorial Boards of international cancer journals (e.g., Breast Cancer Res., Cancer Res.).



Matthew G Vander Heiden (MIT)

Matthew Vander Heiden is an Associate Professor in the Department of Biology at the Massachusetts Institute of Technology, and Associate Director of the Koch Institute for Integrative Cancer Research. He is also an HHMI Faculty Scholar, an Institute Member of the Broad Institute of Harvard and MIT, and an Instructor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School. Dr. Vander Heiden received his MD and PhD degree from the University of Chicago. He also completed clinical training in Internal Medicine and Medical Oncology at the Brigham and Women’s Hospital / Dana-Farber Cancer Institute prior to completing a post-doctoral fellowship at Harvard Medical School. His laboratory studies how metabolism is regulated to meet the needs of cells in different physiological situations. A major focus of his research is the role of metabolism in cancer, and particularly how metabolic pathways support cancer cell proliferation and survival. Using a combination of biochemistry, molecular biology and mouse models, the aim of the Vander Heiden laboratory is to understand how metabolism influences different stages of tumor biology with a goal to improve cancer treatment in the clinic.



Jean-Emmanuel Sarry (Cancer Research Center of Toulouse)



Pierre Sonveaux (Université Catholique de Louvain)

Pierre Sonveaux, PhD, is the Director of the team of Tumor Metabolism (TUMETABO) at the Pole of Pharmacology & Therapeutics of the IREC Institute at the Université catholique de Louvain (UCL) Medical School in Brussels, Belgium. He is Professor of Pharmacology and Senior Research Associate of the Belgian National Fund for Scientific Research (F.R.S.-FNRS). Prof. Sonveaux is President of the International Society of Tumor Metabolism (ISCaM) and a member of the Editorial Boards of Cancer Research, Frontiers in Pharmacology and Cell Stress. Research by his team aim to characterize cancer metabolism in tumors as an organ in order to identify and validate new anticancer targets. Based on collaborative work, key achievements include the identification of a metabolic symbiosis in cancer, and of mitochondrial superoxide as an amenable target for the prevention of cancer metastasis. Prof. Sonveaux received several awards, including the ESTRO-VARIAN-Juliana Denekamp Award 2007, the FECS-EJC Award 2007, the Galien Prize in Pharmacology 2010, the EACR Highly Commended Award in 2010 and the AstraZeneca Prize in Oncology 2016. He is Officer of the Walloon Merit Order, Belgium.

SESSION 2 - Genetic instability and DNA damage response



Jan Hoeijmakers (Erasmus University of Rotterdam)

Jan Hoeijmakers started the molecular analysis of DNA repair in mammals at the Dept. of Genetics (Erasmus Univ. Rotterdam) in 1981. He cloned the first of many human DNA repair genes, allowing elucidation of the underlying mechanisms and the basis of human repair syndromes, such as the cancer-prone xeroderma pigmentosum disorder and the severe neurodevelopmental conditions Cockayne syndrome and trichothiodystrophy. His team pioneered DNA repair dynamics in living cells using novel imaging technologies, generated numerous mouse repair mutants, discovered a strong connection between accumulation of DNA damage and accelerated aging and a trade-off between cancer and aging. The mouse mutants appeared superior models for Alzheimer's disease addressing a tremendous unmet medical need. Accumulation of unrepaired DNA damage causing premature cell death and senescence also triggered an anti-aging 'survival response' which enhances maintenance at the expense of growth resembling the longevity response by dietary restriction. Remarkably, subjecting repair-deficient progeroid mice to actual dietary restriction tripled their lifespan, drastically retarding DNA damage accumulation and accelerated aging most impressively neurodegeneration. In addition he discovered that accelerated and normal aging are associated with transcriptional stress due to stochastic DNA damage affecting gene expression and that dietary restriction counteracts the declining transcriptional output. These findings open perspectives for preventive interventions for healthy aging, reducing cancer and many aging-related diseases including neurodegeneration, and for therapy of human genome instability syndromes. For his work Jan Hoeijmakers received many prizes and awards.



Steve Jackson (University of Cambridge)

Steve Jackson FRS, FMedSci is University of Cambridge Professor of Biology, and Head of Cancer Research UK Laboratories at the Gurdon Institute. Through his academic research (h-index 121; Google Scholar), Steve has identified key principles by which cells respond to and repair DNA damage. In doing so, he identified many DNA repair proteins, established how they function, and helped define how their dysfunction leads to cancer and other age-related diseases. Steve has received various prizes, including the 2015 Gagna and van Heck Prize for Medicine, the 2016 King Faisal International Prize for Science, the 2016 AH. Heineken Prize for Medicine, and the 2017 Genome Stability Network Medal. To translate his work towards patient benefit, Steve founded and then scientifically led the drug-discovery company KuDOS Pharmaceuticals Ltd., which was subsequently acquired by AstraZeneca. Several KuDOS-generated drugs are currently in clinical trials. The most advanced of these drugs, olaparib/Lynparza™, inhibits the DNA-repair enzyme PARP, and enhances cancer-cell killing by radiotherapy and chemotherapies. Moreover, Steve and colleagues showed that PARP inhibitors exhibit striking cytotoxicity towards cancer cells lacking BRCA1 or BRCA2 function. This work thus validated a therapeutic concept that Steve articulated in his 1997 KuDOS Business Plan: killing cancer cells with defects in one DNA repair system by targeting their functional dependency on another DNA repair system, but having little effect on normal cells with the full DNA-repair repertoire. In 2014, olaparib/Lynparza received FDA and EMA approval for treating ovarian cancers with BRCA1/2 mutations, and is now prescribed in 150 countries worldwide. Lynparza/olaparib is the world's first marketed DNA-repair-enzyme inhibitor, the first marketed PARP inhibitor, the first drug exploiting the so-called "synthetic

lethality” principle, and the first cancer medicine targeting inherited predisposition. Ongoing clinical trials are highlighting exciting potential for olaparib and other PARP inhibitors in many other cancers. In 2010, Steve founded Mission Therapeutics Ltd. (Babraham, Cambridge) to exploit recent advances in protein ubiquitylation and deubiquitylation to derive new medicines for cancer, neurodegenerative disorders and other diseases. Steve’s academic laboratory is currently further defining mechanisms of DNA repair and associated processes, with a view to identifying new therapeutic opportunities.



Mark O'Connor (Astra-Zeneca)

Mark is Chief Scientist in Oncology at AstraZeneca (AZ), based in Cambridge, United Kingdom, where he heads up the DNA Damage Response (DDR) strategic biology area. He earned a Ph.D. in biochemistry from Bristol University and carried out his postdoctoral research at the Institute of Molecular and Cell Biology in Singapore, working on the biology of human papillomavirus and the link to cervical cancer. In 1999, Mark returned to the UK to become research team leader at the Cambridge start-up and DDR specialist biotech company KuDOS, and was promoted to Chief Scientist there in 2009. Since 2006, when AstraZeneca acquired KuDOS, Mark has provided scientific leadership on olaparib (Lynparza), the first-in-class oral poly (ADP-ribose) polymerase (PARP) inhibitor, through its transfer to AZ and approval in the United States and Europe in 2014. Mark also championed the in-licensing of the WEE1 inhibitor (AZD1775) in 2013 and has played a key role in the growth of DDR within AZ to an industry-leading portfolio comprising seven DDR projects with six inhibitors currently in clinical development. As well as being a named inventor on multiple patents, Mark has publications that include papers in Cell, Molecular Cell, Nature Cell Biology and New England Journal of Medicine.



Gaëlle Legube (Center for Integrative Biology, Toulouse)

After a PhD in the lab of Didier Trouche in Toulouse on the regulation of a histone acetyltransferase Tip60, Gaëlle Legube joined the group of Asifa Akhtar at EMBL to work on dosage compensation in *Drosophila*. There, she started to use genome wide approaches and reported the first high resolution profile of the dosage compensation complex on the chromosome X using ChIP-chip. After obtaining a permanent position at the CNRS in France and spending few years as a staff scientist in the lab of D. Trouche, she started her own group at the Center for Integrative Biology (CIB) in Toulouse in 2011. She was awarded the Bronze medal from the CNRS for her initial work. More specifically, her lab developed an original system (called DiVA for DSB Inducible via AsiSI), to induce multiple sequence-specific DNA Double Strand Breaks (DSB) widespread across the genome. Using this system her lab investigates several uncovered aspects of the relationship between chromatin and DSB repair, mostly using genome wide approaches.

Jean-Marc Egly

SESSION 3 - Epigenetics - Non coding genome and cancer

This session has been organised with the support of Fondation Toulouse Cancer Santé



#CancerTousConcernés




Maarten van Lohuizen (The Netherlands Cancer Institute)



Ramiro Garzon (The Ohio State University)


Ramiro Garzon is an Associate Professor of Medicine in the Division of Hematology, and a co-leader of the Leukemia Research Program at The Ohio State University (OSU) Comprehensive Cancer Center, Columbus, Ohio. He received his M.D. from the National University School of Medicine, Cordoba, Argentina. He trained in the Medicine program at Yale affiliated Danbury Hospital, Connecticut and subsequently completed a hematology/oncology fellowship at Thomas Jefferson University, Philadelphia. His research focuses on noncoding RNA expression and function in hematopoiesis and leukemia. He has published more than 90 peer-reviewed articles and is the principal investigator of several federal research grants. He has received the Kimmel Translational award, the Leukemia and Lymphoma Scholar Award and the American Cancer Society Research Scholar Award. He is currently a permanent member of the Clinical Oncology Study section at the National Institute of Health and a member of the Scientific Committee on Transplantation Biology and Cellular Therapies of the American Society of Hematology.



Maite Huarte (University of Navarra)

Dr. Maite Huarte obtained her PhD at National Center for Biotechnology (CSIC) in Universidad Autónoma de Madrid. Her postdoctoral work was carried out first in Harvard Medical School in Dr. Yang Shi's laboratory where she identified new histone demethylase enzymes and their contribution to the epigenetic landscape of cells. Later, she worked in John Rinn's laboratory at the Broad Institute of Harvard and MIT, studying the role of long noncoding RNAs (lncRNAs) in gene regulation.

Since 2011 she leads a research group at CIMA (University of Navarra) that investigates how long noncoding RNAs contribute to the mechanisms of gene regulation at the epigenetic and non-epigenetic levels in cancer cells. To reach these goals, they combine functional genomics with molecular and cell biology techniques, in vivo studies, as well as the analysis of patient samples.



François Payre (Center for Integrative Biology, Toulouse)

SESSION 4 - Cancer Immunotherapy, from bench to bed



Jolanda De Vries (Radboud University Nijmegen)

Jolanda de Vries is Professor at the Department of Tumor Immunology at the Nijmegen Centre for Molecular Life Sciences. She was one of the pioneers to translate dendritic cell biology into potential clinical applications. The first clinical phase I/II studies in which patients were vaccinated with DCs loaded with tumor-specific peptides were initiated in 1997. She also developed a novel immuno-monitoring assay that is highly predictive for extended survival after vaccination with DCs. Her primary scientific interest continues along the line of DC-immunotherapy and in particular the migration and imaging of DC. For example, in-vivo imaging of ex-vivo labeled cells using MRI. New opportunities for other cell-types [e.g. subsets of DCs] are now being developed.

Breakthrough discoveries

- Maturation of in-vitro generated monocyte-derived DC for vaccination of cancer patients is essential for antitumor immunity.
- Tumor specificity of skin infiltrating lymphocytes obtained from DC-induced DTH sites correlates with clinical outcome in melanoma patients vaccinated with DC either loaded with tumor-associated peptides or mRNA encoding tumor-associated antigens.
- Plasmacytoid DC can take up antigen via FcγRII and are able to cross present antigen to CD8 T cells.
- Platinum chemotherapy has a positive effect on DC induced immune responses in vitro by inhibiting STAT6 and thereby inhibiting immune inhibitory molecule expression on DC.
- Vaccination with naturally occurring peptide-loaded blood DC are able to induce antitumor responses in cancer patients and thereby have a beneficial effect on clinical outcome.



Nathalie Rufer (University of Lausanne)

Dr. Nathalie Rufer received her PhD from the University of Geneva in 1996. She carried out her post-doctoral work at the Terry Fox Laboratory in Vancouver (Canada) before joining in 2001, the Swiss Institute for Cancer Research (ISREC) as an associate scientist within the Lausanne Oncology program. Since 2009, she has been appointed by the Lausanne University Hospital Center (CHUV), and affiliated to the Ludwig Center for Cancer Research. In 2012, Nathalie Rufer finished her full education in clinical medicine at the University of Lausanne and joined the Department of Oncology led by Prof. George Coukos. Since January 2013, she is extending her research activities together with her clinical education in internal medicine, in oncology and currently in hematology.

The Rufer lab studies T cell responses against tumor antigens in cancer patients following therapeutic vaccination and naturally occurring immune responses, with the major goals to advance our knowledge of T cell mediated protection from human disease and to improve T cell based therapy in the fight against cancer. Three aspects of T cell-mediated immunity are of prime interest to us; (i) the identification of T cell attributes [e.g. memory versus effector] following immune-based therapy in cancer patients, (ii) the T cell clonotype repertoire and its persistence over time against cancer and chronic infection

with herpes viruses, and (iii) TCR-pMHC binding interactions and structure/function relationships of tumor- and virus-specific CD8 T cell clonotypes combined with novel technologies (i.e. NTAmers). Another main focus of our team lies in the development of adoptive cell transfer strategies using engineered T cells. Specifically, we are investigating on approaches to optimize the TCRs with the aim to increase their affinities to cognate tumor antigens, while characterizing the regulatory mechanisms involved in T cell activation, signaling and subsequent function in those TCR-engineered T cells. Understanding TCR-pMHC affinity-mediated regulations and identifying optimized tumor antigen-specific TCRs directly contributes to the rational development of adoptive cell therapy.



Jean-Philippe Girard (Institute of Pharmacology and Structural Biology, Toulouse)

Jean-Philippe Girard currently holds a position of Senior Research Director at Inserm and is the Director of the Institute of Pharmacology and Structural Biology (IPBS), a large Research Center from the CNRS and the University of Toulouse (France). He received his Ph.D. in Molecular Biology from the University of Toulouse and did his postdoctoral training in Immunology and Vascular Biology at Harvard Medical School (USA). Jean-Philippe Girard's research focuses on the role of high endothelial venules (HEVs) and IL-33 cytokine in homeostasis, inflammation and cancer. HEV blood vessels function as portals of entry for lymphocytes into lymphoid organs. A few years ago, he discovered with his team that blood vessels with HEV characteristics are also frequently found in solid tumors, in association with cytotoxic T cell infiltration. Contrary to the dogma that blood vessels facilitate tumor growth, tumor-associated HEVs correlated with favorable clinical outcome in breast cancer. These studies introduced the novel concept that blood vessels in the tumor microenvironment are not all the same and that some types of blood vessels (i.e. tumor-associated HEVs) can contribute to tumor suppression rather than tumor growth. Dr. Girard was awarded several prizes for his work, including the CNRS Silver Medal 2013, "Grand Prix de Cancérologie 2012" from the National Academy of Sciences, "Prix de Cancérologie 2013" from the National Academy of Medicine, and "Prix Scientifique 2016" from 'Fondation pour la Recherche Médicale' (FRM).

SESSION 5 - New therapeutic strategies: Combined therapies – Radiotherapy, Proton therapy



Jim Metz (University of Pennsylvania)

James M. Metz, MD, Chair of the Department of Radiation Oncology in the Perelman School of Medicine at the University of Pennsylvania. Dr. Metz is a radiation oncologist who specializes in the treatment of gastrointestinal malignancies and the retreatment of previously irradiated tumors. He has led numerous clinical trials in gastrointestinal cancer with a particular interest in maintaining normal organ function. His clinical research emphasizes multimodality therapies for locally advanced gastrointestinal malignancies. Dr. Metz led the development of the Roberts Proton Therapy Center, the largest proton center in the world, which opened in 2010. He has been an international leader in the integration of proton therapy in the cancer treatment paradigm. He has held a series of administrative positions within the department, beginning in 2005, when he was appointed Director of Clinical Operations. In 2009, he was appointed Vice Chair of the Clinical Division in Radiation Oncology, and in 2010 became the Director of Quality Assurance and Quality Improvement. In 2014, he was appointed Vice Chair of the department. He has served as Professor of Radiation Oncology at the Perelman School of Medicine and was the Associate Director for Clinical Services and Programs at the Abramson Cancer Center of the University of Pennsylvania. As the long time Editor-in-Chief [and now Executive Director] of OncoLink, an award winning website and resource for cancer information, Dr. Metz pioneered the use of online cancer survivorship care plans and web-based cancer education and information. OncoLink (www.OncoLink.Penn.edu) has been named on numerous occasions as one of the Top 10 medical websites in the world by the National Library of Medicine. Dr. Metz is board certified in radiation oncology and is a member of the American Society of Clinical Oncology (ASCO) and the American Society of Therapeutic Radiation Oncology (ASTRO).



Gillies McKenna (University of Oxford)

A native of Scotland, Professor Gillies McKenna graduated in Zoology in 1972 from the University of Edinburgh; he then studied in the US for an M.D. and a Ph.D. in Cell Biology from Albert Einstein College of Medicine in New York. After postgraduate training at Johns Hopkins Hospital and the US National Cancer Institute, Professor McKenna joined the Faculty of the University of Pennsylvania School of Medicine in Philadelphia in 1987, where he rose to become the Henry K. Pancoast Professor and Chairman of Radiation Oncology. His major research interest is the study of the molecular mechanisms underlying the resistance of some cancers to treatment with radiation or with chemotherapy. He is particularly interested in developing strategies to render some of the most resistant tumours more sensitive to treatment and is working to bring some of his research discoveries into clinical trial in our area. Professor McKenna has received several awards and honours including a Scholar's Award from the Radiological Society of North America, a Career Development Award from the American Cancer Society, the Weiss medal from the Association for Radiation Research, the Röntgen Medal from the Deutsches Röntgen Museum, Germany and most recently the Gold Medal from the Royal College of Radiologists. He was a member of the Board of Scientific Advisors of the US National Cancer Institute. Professor McKenna moved to Oxford in 2005 and is currently the Director of the CRUK/MRC Oxford Institute for Radiation Oncology. He was Head of the Department of Oncology from 2010 to April 2017. He works closely and serves on scientific boards with external funding bodies and partners. He is a Fellow of the Royal College of Radiologists, the Academy of Medical Sciences and of the Institute of Biology.



Julien Mazières (IUCT-Rangueil Larrey, Cancer Research Center of Toulouse)


Julien Mazières, MD, PhD, is pulmonologist and an oncologist, heading the thoracic oncology program at Toulouse University Hospital in France and Toulouse Cancer Institute (IUCT). He also serves as a professor of pulmonology there. He is a researcher at Institut National de la Santé et de la Recherche Médicale (Inserm) in the Cancer Research Center of Toulouse (CRCT, UMR1037). Professor Mazières received his medical degree in Toulouse and completed specialty training in pulmonology and oncology at the University of Toulouse, where he also earned a master's degree in molecular and cellular biology, and a doctoral degree at Paul Sabatier University, also in Toulouse. He has worked as a research fellow in thoracic oncology lab in San Francisco (UCSF). His main research interests are early diagnosis, targeted therapy, immunotherapy and multimodal treatment for lung cancer, mesothelioma, and thymoma. He is also involved in translational research related to lung cancer in women and in prognostic and predictive biomarkers. In his research for Inserm, Professor Mazières is working on fundamental cancer research with a special focus on RhoGTPases, tumor invasion and resistance to targeted therapy. His work has been published in more than 140 peer-reviewed publications including *The Lancet*, *The Lancet Oncology*, the *Journal of Clinical Oncology*, and *Cancer Research*.

SESSION 6 - Clinical research on Melanoma



Richard Marais (Cancer Research UK Manchester Institute)

Professor Marais is the Director of the CRUK Manchester Institute at The University of Manchester and a Professor of Molecular Biology. He has advanced our understanding of the role of BRAF in cancer and in 2004 he validated mutant BRAF as a therapeutic target in melanoma. He has since pioneered translational research in melanoma, studying basic biology to understand the mechanisms of resistance to targeted therapies. He was a member of the 2012 winning team for the AACR Team Science Award for its cancer drug discovery programme and more recently has developed anticancer drugs that target RAF kinases. In 2017, he received the Translational and Clinical Research Award from The ARC Foundation Léopold Griffuel Awards and an Outstanding Research Award from The Society of Melanoma Research. His research has contributed to public health information regarding the use of sunscreen and the need to combine this with other sun avoidance strategies to reduce the risk of developing melanoma. Professor Marais continues to focus on understanding the pathological basis of melanoma to deliver benefit to patients.



Céleste Lebbé (Hôpital Saint-Louis, APHP)



Nicolas Meyer (IUCT-Oncopole, Cancer Research Center of Toulouse)



SCIENTIFIC PROGRAM

General Program

	Monday 5 Feb. 2018	
Morning 9h-12h15	SESSION 1 Metastasis and microenvironment Metabolism SAINT EXUPERY AUDITORIUM	
Lunch 12h-14h	Company and technology presentations SAINT EXUPERY AUDITORIUM	
	Poster session / Lunch CARAVELLE ROOM	
	Industrial presentations CARAVELLE ROOM	
Afternoon 14h-17h30	SESSION 2 Genetic instability and DNA damage response SAINT EXUPERY AUDITORIUM	
Evening	18H30 Welcome cocktail SALLE DES ILLUSTRES CITY HALL OF TOULOUSE	
	20H30 Gala dinner « MA BICHE SUR LE TOIT RESTAURANT »	

	Tuesday 6 Feb. 2018	Wednesday 7 Feb. 2018
	SESSION 3 Epigenetics - Non coding genome and cancer SAINT EXUPERY AUDITORIUM	SESSION 5 New therapeutic strategies : Combined therapies - Radiotherapy, Proton therapy SAINT EXUPERY AUDITORIUM
	Company and technology presentations SAINT EXUPERY AUDITORIUM	Company and technology presentations SAINT EXUPERY AUDITORIUM
	Poster session / Lunch CARAVELLE ROOM	Poster session / Lunch CARAVELLE ROOM
	Industrial presentations CARAVELLE ROOM	Industrial presentations CARAVELLE ROOM
	SESSION 4 Cancer immunotherapy from bench to bed SAINT EXUPERY AUDITORIUM	SESSION 6 Clinical research on melanoma SAINT EXUPERY AUDITORIUM
	18H00-20H00 General public conference SAINT EXUPERY AUDITORIUM	
		20h00-22h00 Medical session SAINT EXUPERY AUDITORIUM

Detailed Program

0	Welcome Introduction	05/02/18 08:30	05/02/18 09:00			
1	SESSION 1 Metastasis and microenvironment Metabolism SAINT EXUPERY AUDITORIUM	09:00	09:30	Liquid Biopsy: Technologies and clinical applications	Klaus Pantel	University Medical Center Hamburg-Eppendorf
2		09:30	10:00	Influence of the tumor environment on cancer cell metabolism	Matthew G Vander Heiden	MIT
4		10:00	10:15	PGC - 1alpha controls an onco - metabolic program to limit prostate cancer aggressiveness	Frédéric Bost	Cancer Research Center of Toulouse (CRCT) C3M
3		10:15	10:45	Metabolic flexibility and mitochondrial OxPHOS activity in the drug resistance of leukemia	Jean-Emmanuel Sarry	Cancer Research Center of Toulouse (CRCT)
	COFFEE BREAK POSTER SESSION CARAVELLE ROOM	10:45	11:15			
5	SESSION 1 Metastasis and microenvironment Metabolism SAINT EXUPERY AUDITORIUM	11:15	11:30	Periprostatic adipose tissue promotes prostate cancer invasion: role of oxidative stress & regulation by obesity	Aurélie Toulet	IPBS
6		11:30	11:45	Na ⁺ leak governs pacemaking activity of cancer cells required for the metastatic disease development	Oksana lamshanova	Laboratory of Cell Physiology, Inserm U1003, University of Lille
7		11:45	12:15	A mitochondrial switch promotes tumor metastasis	Pierre Sonveaux	Université Catholique de Louvain
1	InvivoGen SAINT EXUPERY AUDITORIUM	12:15	12:20	STING tumors for immunotherapy	Eric Perouzel	
2	I.Céram SAINT EXUPERY AUDITORIUM	12:20	12:25	Porous alumina ceramic as a vector for local treatment for bone infection or bone tumor	Christelle Arico	
3	Urosphère SAINT EXUPERY AUDITORIUM	12:25	12:30	Urosphere/uroleads : your oncology partners	Sophie Chabot	
4	Vita API SAINT EXUPERY AUDITORIUM	12:30	12:35	Selenium-enriched Arthrospira platensis as new vector for anticancer drug delivery	Catherine Riva	

5	Inovotion SAINT EXUPERY AUDITORIUM	12:35	12:40	A Unique In Vivo Assay for Your Oncology Drug Candidates	Arnaud Peyronnier	
6	Essen Bioscience SAINT EXUPERY AUDITORIUM	12:40	12:45	Live Imaging and Cell Analysis for Immuno-oncology Studies, How the InCuCyte Empowers Cell Based Research	Jean-Baptiste Pénigault	
LUNCHTIME POSTER SESSION CARAVELLE ROOM		12:15	14:00			
1	SESSION 2 Genetic instability and DNA damage response SAINT EXUPERY AUDITORIUM	14:00	14:30	Maintaining Nature's Perfection: the impact of DNA repair on sustained health	Jan Hoeijmakers	Erasmus Univer- sity of Rotterdam
2		14:30	15:00	Cellular responses to DNA damage: from mechanistic insights to applications in cancer therapy	Steve Jackson	University of Cambridge
3		15:00	15:15	Cell fusion contributes to sarcoma formation and progression	Lucile Delespaul	Cancer Research Center of Toulouse (CRCT)
4		15:15	15:45	Title to be communicated	Mark O'Connor	Astra-Zeneca
COFFEE BREAK POSTER SESSION CARAVELLE ROOM		15:45	16:15			
5	SESSION 2 Genetic instability and DNA damage response SAINT EXUPERY AUDITORIUM	16:15	16:45	Chromatin and Chromosome dynamics during DNA Double Strand break repair	Gaëlle Legube	Center for Integrative Biology, Toulouse
6		16:45	17:00	Post - transcriptional regulation of mRNA location and translation controls oncogene expression in lymphocytes.	Manuel Daniel Diaz-Munoz	Centre de Physiopatho- logie Toulouse - Purpan, Inserm UMR1043 / CNRS U5282
7		17:00	17:30	CSA/CSB, an ubiquitin- proteasome complex in transcription coupled repair?	Jean-Marc Egly	IGBMC

1	SESSION 3 Epigenetics Non coding genome and cancer #CancerTousConcernés  SAINT EXUPERY AUDITORIUM	06/02/18 09:00	06/02/18 09:30	Context - dependent roles of polycomb repressors in cancer and development	Maarten van Lohuizen	The Netherlands Cancer Institute
2		09:30	10:00	Expression and function of Long non coding RNAs in Acute Myeloid Leukemia	Ramiro Garzon	The Ohio State University
3		10:00	10:15	Control of gene expression in senescence through transcriptional read - through of convergent protein - coding genes	Estelle Nicolas	LBCMCP Center for Integrative Biology (CIB)
COFFEE BREAK POSTER SESSION CARAVELLE ROOM		10:15	10:45			
4	SESSION 3 Epigenetics Non coding genome and cancer #CancerTousConcernés  SAINT EXUPERY AUDITORIUM	10:45	11:15	Title to be communicated	Maïte Huarte	University of Navarra
5		11:15	11:30	A noncoding function of TYRP1 mRNA promotes melanoma growth	Marie-Dominique Galibert	Institut de Génétique et Développement de Rennes, CNRS UMR6290, Université de Rennes
6		11:30	12:00	Peptides produced by apparently non-coding RNAs in the control of embryonic development and adult stem cells	Francois Payre	Center for Integrative Biology, Toulouse
1	Institut de Recherche Pierre Fabre SAINT EXUPERY AUDITORIUM	12:00	12:05	Pierre Fabre Oncology Presentation	Anna Kruczynski	
2	10X genomics SAINT EXUPERY AUDITORIUM	12:05	12:10	Single Cell Analysis with 10x Genomics	Mickael Ploquin	
3	GamaMabs SAINT EXUPERY AUDITORIUM	12:10	12:15	GM102, a first-in-class immuno-enhancer antibody targeting AMHR11	Stéphane Degove	
4	Antineo SAINT EXUPERY AUDITORIUM	12:15	12:20	Development of in vivo tumor models resistant to reference treatments	Chloé Grasselly	
5	Miltenyi Biotec SAINT EXUPERY AUDITORIUM	12:20	12:25	Immuno-Oncology – Activities and solutions offered by Miltenyi Biotec	Guillaume Lay	
6	Acobiom SAINT EXUPERY AUDITORIUM	12:25	12:30	Acobiom : A New approach for personalized in pancreatic cancer	Didier Ritter	

7	LGC SAINT EXUPERY AUDITORIUM	12:30	12:35	ATCC Advanced Cancer Models	Romuald Menth	
LUNCHTIME POSTER SESSION CARAVELLE ROOM		12:00	14:00			
0	ESOF Presentation	14:00	14:15			
1	SESSION 4 Cancer Immunotherapy, from bench to bed SAINT EXUPERY AUDITORIUM	14:15	14:45	Natural circulating dendritic cells: Key for antitumor immunity?	Jolanda de Vries	Radboud Univer- sity Nijmegen
2		14:45	15:00	Regulation of immune checkpoint expression	Don-Marc Franchini	Cancer Research Center of Toulouse (CRCT)
4		15:00	15:30	Identifying high - avidity and high - quality individual T lymphocytes in cancer patients	Nathalie Rufer	University of Lausanne
COFFEE BREAK POSTER SESSION CARAVELLE ROOM		15:30	16:00			
3	SESSION 4 Cancer Immunotherapy, from bench to bed SAINT EXUPERY AUDITORIUM	16:00	16:15	Machine learning unveils sculpturing of CD8+ T cell compartment by tumor progression predictive of need for therapy	Pauline Gonnord	Cancer Research Center of Toulouse (CRCT)
5		16:15	16:45	Tumor-associated HEVs: specialized blood vessels for lymphocyte entry into tumors	Jean-Philippe Girard	Institute of Pharmacology and Structural Biology, Toulouse
6		16:45	17:00	Monitoring PD - L1 expression on circulating tumor cells (CTCs) and circulating myeloid derived - suppressor cells (MDSC) during anti - PD1 therapy	Myriam Delaunay	CHU Larrey, Cancer Research Center of Toulouse (CRCT)
1	Public Conference (french only) SAINT EXUPERY AUDITORIUM	18:00	20:00	Is there a part of chance in cancer?	Gilles Favre	Cancer Research Center of Toulouse (CRCT) / IUCT-Oncopole, Toulouse
2	Public Conference (french only) SAINT EXUPERY AUDITORIUM	18:00	20:00	Active prevention of cancer	Cyrille Delpierre	Cancer Research Center of Toulouse (CRCT)/ UPS, Toulouse
3	Public Conference (french only) SAINT EXUPERY AUDITORIUM	18:00	20:00	Immunotherapies: new hopeful treatments	Maha Ayyoub	Cancer Research Center of Toulouse (CRCT) / IUCT-Oncopole, Toulouse

1	SESSION 5 New therapeutic strategies: Combined therapies Radiotherapy Proton therapy SAINT EXUPERY AUDITORIUM	07/02/18 09:00	07/02/18 09:30	Title to be communicated	Jim Metz	University of Pennsylvania
2		09:30	10:00	Title to be communicated	Gillies McKenna	University of Oxford
3		10:00	10:15	Identification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacodynamics	Fabien Despas	Toulouse University Hospital
4		10:15	10:30	Immunotherapy against melanoma by pIRE - IL12 Gene electrotransfer (GET): a pre-clinical investigation	Muriel Golzio	IPBS - CNRS
COFFEE BREAK POSTER SESSION CARAVELLE ROOM		10:30	11:00			
5	SESSION 5 New therapeutic strategies: Combined therapies Radiotherapy Proton therapy SAINT EXUPERY AUDITORIUM	11:00	11:15	Translation to the clinic of EVT801: A novel immune - oncology agent for addressing innate - driven immunosuppression into the tumor microenvironment and expand patient population responding to immune checkpoint therapies	Pierre Fons	EVOTEC
6		11:15	11:30	Reverse immunosuppression and metastasis formation in pancreatic cancer through pharmacological targeting of cancer associated fibroblasts	Rémi Samain	Cancer Research Center of Toulouse (CRCT)
7		11:30	12:00	Overcoming resistance to targeted therapies in lung cancer	Julien Mazières	IUCT-Rangueil Larrey, Cancer Research Center of Toulouse (CRCT)
1	Oncomedics SAINT EXUPERY AUDITORIUM	12:00	12:05	Functional assay to personalized all cancer treatment for all patient	Christophe Lautrette	
2	Vect-Horus SAINT EXUPERY AUDITORIUM	12:05	12:10	Targeted delivery to Tumors via Receptor Mediated Transport - Radiotherapy and Imaging	Cédric Malicet	

3	Chromalys SAINT EXUPERY AUDITORIUM	12:10	12:15	Micro-technology for tumor detection and tracking during radiotherapy	Marc Verelst	
4	Easy Chelators SAINT EXUPERY AUDITORIUM	12:15	12:20	Innovative Radiopharmaceuticals to fight against cancer	Jean-Marc Joumier	
5	Screencell SAINT EXUPERY AUDITORIUM	12:20	12:25	Unique Medical device (CE-IVD) for capturing and harvesting circulating tumor cells (CTCs), liquid biopsy of cancer: Clinical applications	Naoual Linda Benali Furet	
6	Medexprim SAINT EXUPERY AUDITORIUM	12:25	12:30	Unleash the potential of biomedical images archives and associated data for research	Karine Seymour	
LUNCHTIME POSTER SESSION CARAVELLE ROOM		12:00	14:00			
1	SESSION 6 Clinical research on Melanoma SAINT EXUPERY AUDITORIUM	14:00	14:30	Precision medicine for melanoma: are we there yet?	Richard Marais	Cancer Research UK Manchester Institute
2		14:30	14:45	SLITRK6 : new target for the treatment of BRAF - mutant metastatic melanoma ?	Magdalena Pohorecka	Cancer Research Center of Toulouse (CRCT)
3		14:45	15:15	Title to be communicated	Céleste Lebbé	Hôpital Saint-Louis, APHP
COFFEE BREAK POSTER SESSION CARAVELLE ROOM		15:15	15:45			
4	SESSION 6 Clinical research on Melanoma SAINT EXUPERY AUDITORIUM	15:45	16:15	Dermatologic reactions to immune checkpoint inhibitors	Vincent Sibaud	IUCT-Oncopole, Cancer Research Center of Toulouse (CRCT)
5		16:15	16:30	Targeting sphingosine kinase - 1 enhances anti - melanoma immune response and improves efficacy of immune checkpoint blockade	Caroline Imbert	Cancer Research Center of Toulouse (CRCT)
6		16:30	17:00	TNF α inhibitors as immune checkpoint inhibitors for the treatment of melanoma: a new paradigm in tumor oncology ?	Nicolas Meyer	IUCT-Oncopole, Cancer Research Center of Toulouse (CRCT)
MEDICAL SESSION (FRENCH ONLY) SAINT EXUPERY AUDITORIUM		20:00	22:00			

POSTERS

Name	Title	Affiliation	Country
Amandine ALARD	eIF4E3, a regulator of monocytic differentiation in AML?	CRCT, Inserm	France
Silvia ARCUCCI	Role of the class IA PI3K p110beta subunit in pancreatic cancer	Inserm	France
Assia ASRIR	HIGH ENDOTHELIAL VENULES (HEV): MAJOR GATEWAYS FOR ANTI-TUMOR CYTOTOXIC T CELLS AND NEW PARTNERS OF CANCER IMMUNOTHERAPY	IPBS	France
François AUTELITANO	Proteomics and Metabolomics for Mechanistic Insights and Biomarker Discovery in Cancer Disease	EVOTEC FRANCE SAS	France
Francois AYMARD	CRISPR/Cas9 applied to drug discovery at Evotec	Evotec	France
Francois AYMARD	'TargetDBR' -Exploiting synthetic lethal, high content and functional cellular reporter assays to accelerate DNA repair targeted drug discovery	Evotec	France
Hafid BELHADJ-TAHAR	Preclinical study of new potential anticancer agent derived from [188Re]rhenium Nitro-Imidazole ligand loaded 5th generation poly-L-Lysine dendrimer.	AFPREMED	France
Sara BELKHEIRI	Epidural metastasis of thyroid papillary carcinoma : A case report	centre Mohamed VI pour le traitement des cancers CHU Casablanca	Morocco
Sara BELKHEIRI	Large cell neuroendocrine carcinoma of the larynx: A case report	CHU casablanca service d'oncologie radiothérapie	Morocco
Sara BELKHEIRI	Place and role of radiation therapy in the treatment of thymic epithelial tumors	CHU casablanca Maroc; centre Mohamed VI pour le traitement des cancers	Morocco
Hanane BENTURKIA	Cancer in Setif area: Incidence, trend, survival and political impact	Laboratory of Environment and Health, Setif University, Algeria	Algeria
Claire BERAUD	Development and characterization of an extensive panel of patient-derived tumor xenograft (PDX) models for prostate, bladder and kidney cancers	UROLEAD	France
David BERNARD	Optimization of synchronization experiments using a checkpoint-oriented cell cycle simulator	ITAV & IRIT	France
Takiy BERRANDOU	Tobacco smoke, genes involved in the metabolism of xenobiotics and breast cancer risk	Inserm-CESP	France
Alexandre BOKHOBZA	Study of ORAI channel remodelling	Inserm U1003	France
Françoise BONO COLOMBIÉ	AsiDNA and HDAC inhibitors: a cross-potential team working to kill tumor cells	onxeo	France
Julie BORDENAVE	Development of an anti-TAM antibody for anticancer therapies	CRCT	France

Ghina BOUABOUT	Preclinical evaluation of polyethylenimine-mediated RNA interference of Polo-Like Kinase 1 gene for ultrasound image-guided treatment of hepatocellular carcinoma	IGBMC-ICS	Finland
Cedric BOULARAN	NON NATURAL CYCLIC DINUCLEOTIDES (CDNs) TO INDUCE STIMULATOR OF INTERFERON GENES (STING)-DEPENDENT ANTITUMOR IMMUNITY.	INVIVOGEN	France
Ghizlane BOUNDER	TNF alpha Receptor 1 Promoter Gene Polymorphisms and Susceptibility to Gastric Cancer Related to H. Pylori Infection in Moroccan Population	Institut Pasteur du Maroc and Faculty of Sciences Ben M'sik, University Hassan II	Morocco
Sébastien BRITTON	Mechanisms antagonizing Ku at single-ended DNA double-strand breaks	IPBS CNRS-University of Toulouse	France
Louis BUSCAIL	MULTICENTER PHASE-2 GENE THERAPY TRIAL FOR ADVANCED PANCREATIC CANCER: RATIONALE AND DESIGN	Service de Gastroentérologie et Pancréatologie, CHU Toulouse Rangueil et Université Paul Sabatier Toulouse3	France
Jean CACHEUX	Rapid detection of microRNA biomarkers through a nanofluidic-embedded biosensor coupled to molecular beacon probes	CRCT-Inserm and LAAS-CNRS	France
Nina CAILLET	The tyrosine kinase NPM-ALK mediates malignant transformation of normal human CD4 T lymphocytes	CRCT - Inserm UMR1037	France
Patrick CALSOU	The DNA binding polyamine moiety in the vectorized DNA topoisomerase II inhibitor F14512 alters reparability of the consequent enzyme-linked DNA double strand breaks	IPBS, CNRS, UMR5089	France
Camille SPINNER	A new E3 ubiquitin ligase regulates the immune response in colon cancer	Institut de Pharmacologie et Biologie Structurale - CNRS UMR 5089	France
Hadjira CHAOUICHE	Environmental risk factors and breast cancer at wilaya of Setif	Department of Epidemiology and Preventive Medicine - CHU Setif Algeria	Algeria
Hadjira CHAOUICHE	Time trends of cancer incidence and survival in Setif, Algeria, 1986-2010.	Laboratory of Environment and Health, Setif University, Algeria	Algeria
Pierre CORDELIER	The antitumoral activity of TLR7 ligands is corrupted by the microenvironment of pancreatic tumors	Cancer Research Centre of Toulouse Inserm U1037	France
Mathilde COUSTETS	Specific detection of the Thomsen-Friedenreich antigen by Xerocomus Chrysenteron Lectin : an in vitro and in vivo study for imaging epithelial ovarian cancer	Urosphere / Institute of Pharmacology and Structural Biology	France
Marina DALL'OSTO	The specialized DNA polymerase Kappa required to stabilize the checkpoint kinase Chk1	Cancer Research in Cancerology of Toulouse - Inserm	France
Pauline DESHORS	Irradiation-induced transdifferentiation of Glioblastoma Stem Cells into endothelial cells	Inserm U1037 CRCT	France

Frédérique FALLONE	Adipocytes promote breast cancer resistance to chemotherapy, a process amplified by obesity: role of the major vault protein (MVP)	IPBS CNRS Toulouse	France
Nadim FARES	Toll-like Receptor 3 suppression as an escape mechanism to apoptosis associated with poor prognosis in hepatocarcinoma	Cancer Research Center of Lyon/ Toulouse Hospital	France
Sarah FIGAROL	Phenotypic characterization of a drug tolerant state induced by targeted therapy in EGFR-mutated lung cancer cells.	Cancer Research Center of Toulouse (CRCT) - Team 3	France
Pierre FONS	Identification of a novel non-brain penetrant A2AR inhibitor and proof-of-concept of CD73 and A2AR/CD73 small molecule inhibitors for cancer immunotherapy	EVOTEC	France
Audrey FRANCES	Exploring a new function for cytidine deaminase in pancreatic cancer metabolism	Cancer Research Center of Toulouse (CRCT)	France
Mohamed GAMEA	The role of Topoisomerase II-? (TOPO IIA) as a predictive factor for response to neoadjuvant anthracyclines based chemotherapy in locally advanced breast cancer	aswan university	Egypt
Fabien GAVA	Gap junctions contribute to anchorage-independent clustering of breast cancer cells	ITAV CNRS Université Toulouse	France
Francois GHIRINGHELLI	Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRC (MEDITREME)	centre georges francois leclerc	France
Véronique GIGOUX	Targeted Magnetic Intra-Lysosomal Hyperthermia produces lysosomal reactive oxygen species and causes Caspase-1 dependent cell death of cancer cells.	Inserm ERL1226	France
Aurélié GOMES	Reversible growth arrest of 3D tumor spheroids stored in oxygen absorber-induced anoxia	ITAV CNRS Université de Toulouse	France
Valérie GOUAZÉ-ANDERSSON	Inhibition of FGFR1 downregulates stemness, epithelial-mesenchymal transition associated genes and sensitizes glioblastoma tumor spheres to radiotherapy.	Cancer Research Center of Toulouse (CRCT)	France
Virginie GOUBERT	Imaging in cancer immunology: Phenotyping of multiple immune cell subsets in-situ in FFPE tissue sections	PERKIN ELMER	France
Morgane GOURVEST	Long non coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature in NPM1-mutated patients	Cancer Research Center of Toulouse/ Université Toulouse III Paul Sabatier	France
Morgane GOURVEST	Long non coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature in NPM1-mutated patients	Cancer Research Center of Toulouse/ Université Toulouse III Paul Sabatier	France
Chloé GRASSELLY	ESTABLISHMENT AND CHARACTERISATION OF A PRECLINICAL BLADDER MODEL OF RESISTANCE TO IMMUNE CHECKPOINT INHIBITORS	CRCL - ANTINEO	France

Nicolas GUIBERT	Amplicon-Based Next-Generation Sequencing (NGS) of Plasma Cell-Free DNA (cfDNA) for Detection of Driver and Resistance Mutations in NSCLC	IUCT-Rangueil Larrey	France
Julie GUILLERMET-GUIBERT	A phosphoproteomic screening reveals a novel combinative therapeutic strategy to exploit the redundancy of Class I PI3Ks in pancreatic cancer.	Inserm U1037 Cancer Research Center of Toulouse (CRCT)	France
Coralie HOAREAU-AVEILLA	Crosstalk between microRNA and DNA Methylation Offers Potential Biomarkers and Targeted Therapies in ALK-Positive Lymphomas.	Inserm UMR1037	France
Mohsen HOSSEINI	The Role of Oxidative Stress in Chemotherapy-Resistant Human Acute Myeloid Leukemia	Cancer Research Center of Toulouse (CRCT)- Inserm U1037	France
Jean-Philippe HUGNOT	Cellular and molecular characterization of IDH1-mutated diffuse low grade gliomas reveals tumor heterogeneity and absence of EGFR/PDGFR? activation.	Inserm U1051	France
Ahmadaye IBRAHIM KHALIL	Variation of exon 11 of the BRCA1 gene in patients with familial breast cancer at the Mohammed VI center for the treatment of cancers	laboratoire de Physiopathologie et genetique Moleculaire	Morocco
Ahmadaye IBRAHIM KHALIL	Inflammatory breast cancer: experience of center Mohammed VI for the treatment of cancers	Registry Cancers Of Great Casablanca - Morocco	Morocco
Sébastien JAULIAC	Exosome based therapy in advanced breast and pancreatic cancer	Inserm U976	France
Christine JEAN	Fibroblastic FAK controls pancreatic cancer metastasis by enhancing extracellular matrix remodeling	Cancer Research Center of Toulouse (CRCT), team 6 "Protein synthesis & secretion in carcinogenesis",	France
Ilham KHALFAOUI	mélanome malin primitif : à propos d'un cas et revue de la littérature	chu ibn rochd Casablanca - Maroc	Morocco
Stanislaw KWIATKOWSKI	The efficiency of photodynamic therapy mediated by curcumin against human amelanotic melanoma in vitro	Wroclaw Medical University, Poland	Poland
Chaimaa LAHMAMSSI	Extrapulmonary large Cell Neuroendocrine Carcinoma of the nasal cavity: A Case Report and Review of the Literature	chu ibn rochd	Morocco
Chloé LAPLAGNE	Phosphoantigenic activation of Vg9Vd2 T lymphocytes: involvement of RHOB in a lung cancer model	Cancer Research Center of Toulouse (CRCT) - U1037	France
Dorian LARRIEU	A new role for the E3 ubiquitin ligase TRIP12 in mitosis and genomic stability in pancreatic cancer	Equipe 10 - Cancer Research Center of Toulouse (CRCT)	France
Anne-Claire LAVIGNE	MacroH2A1.1, a new epigenetic target for treatment of prostate cancer.	Laboratoire de Biologie Moléculaire Eucaryote (LBME), Center for Integrative Biology (CIB)	France
Pierre LAYROLLE	Organotypic culture and 3D bioprinting of bone tumor models	Inserm UMR1238, PHY-OS, University of Nantes	France

Tom LESLUYES	The CINSARC signature predicts clinical outcome in multiple cancer types	Cancer Research Center of Toulouse	France
Valérie LOBJOIS	Mechanical stress controls the orientation of nuclei and cell division in 3D tumour spheroids	ITAV, CNRS-University of Toulouse	France
Wafaa MAHFOUD	Activation of MAPK and PI3K in melanoma	Laboratoire de Biologie et Santé, URAC-34, Faculté des sciences Ben M'sik, Université HassanII Mohammedia.-Casablanca	Morocco
Ludovic MARTINET	Dysregulated IL-18 critically drives immunosuppression in the multiple myeloma microenvironment.	Inserm	France
Pierre MARTINEZ	Evolution of Barrett's Esophagus through space and time at single-crypt and whole-biopsy levels	Centre de Recherche en Cancérologie de Lyon	France
Charlotte MAULAT	Predictive factors and impact on overall survival (OS) and disease-free survival (DFS) of the tumor regression grade (TRG) of resected colorectal liver metastases (CRLM) after neoadjuvant chemotherapy (NACT).	CHU Toulouse	France
Romuald MENTH	Characterization of hTERT-immortalized Prostate-derived Stromal and Epithelial Cells: an Authentic in vitro Model for Tumour Microenvironment Studies	ATCC-LGC	France
Hind MIMOUNI	La relation entre l'accompagnement infirmier et l'acceptation de la nouvelle image corporelle des patientes mastectomisées	INSTITUT NATIONAL D'ONCOLOGIE DE RABAT MAROC	Morocco
Anne MONTFORT	Combining TNF-targeting antibodies to immune check-point inhibitors in melanoma	Inserm UMR 1037, Cancer Research Center, Toulouse	France
Laetitia MOULY	PARP-1-dependent induction of RND1 transcription confers cell resistance to the topoisomerase I inhibitor camptothecin	Inserm UMR 1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France	France
Alice MUNARETTO	Longitudinal analysis of the effect of the Btk inhibitor ibrutinib on the motility properties of CLL leukemic cells and T cells	Inserm	France
Emmanuelle NOIRRIT-ESCLASSAN	Photobiomodulation in the treatment of pediatric oral mucositis: a feasibility study	CHU Toulouse	France
Justine NOUJARÈDE	Sphingosine 1-Phosphate represses E-cadherin in epidermal keratinocytes and promotes migration of non-invasive melanoma cells	Cancer Research Center of Toulouse (CRCT)	France
Chloé OUDINET	Ontogenic and lineage-specific DNA cytosine demethylation at the IgH constant locus	IPBS UMR 5089 UPS Toulouse	France
Marie-Noëlle PALUDETTO	BIOMIMETIC OXIDATION STUDIES OF TYROSINE KINASE INHIBITORS	Inserm, Cancer Research Center of Toulouse (CRCT)	France
David PIQUEMAL	GemciTest, an innovative and sustainable IVD in pancreatic cancer treatment to improve patient quality of life, patient overall survival and healthcare cost saving	ACOBIOIM	France

Michel POPIELARZ	DISTINGUISHING CELL LINES BY PHENOTYPIC PROFILING	PerkinElmer	France
Fernanda RAMOS	Circulating DNA is a marker of aggressivity in Pancreatic Ductal Adenocarcinoma	Cancer Research Center of Toulouse (CRCT) Inserm	France
Anne-Aur�lie RAYMOND	A combined laser microdissection and proteomic analysis method for identification of robust biomarkers in oncology.	Oncoprot U1053 TBM Core US005	France
Roham SALEK	Hypofractionated accelerated whole breast irradiation for early breast cancer; randomized clinical trial of cosmetic outcome and safety	Mashhad University of Medical Sciences	Iran
Joana SANTOS	Long-range effect of the immunoglobulin heavy chain super-enhancer	IPBS	France
Anna SERWETA	Application of mental training in a patient with breast cancer subjected to radiation therapy. Case study.	University School of Physical Education in Wroclaw	Poland
Fatima SMAGULOVA	Exposure to chlordecone leads to transgenerational effects in murine prostate tissue	Inserm U1085/IRSET	France
Tania SORG	Generation of the Cancer Pathway Prototype - a platform for predictive cancer pathway modeling	PHENOMIN-ICS	France
Dinu STEFAN	Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable high grade gliomas patients - OLA-TMZ-RTE-01 protocol	Centre Franois Baclesse	France
Claire TARDIVEAU	Single cell RNA-seq analysis of High Endothelial Venules (HEVs): blood vessels that mediate lymphocyte entry into lymph nodes and tumors	IPBS-CNRS, UMR 5089	France
Beno�t THIBAUT	Aggressive PDAC with high levels of circulating DNA requires PI3K isoform alpha to accelerate metastatic disease	Inserm - Cancer Research Center of Toulouse (CRCT) - Equipe 17	France
Guy TRAN VAN NHIEU	A BACTERIAL-BASED PEPTIDE PROMOTING CELL ADHESION AND PREVENTING MIGRATION OF MELANOMA CELLS.	CIRB - Coll�ge de France	France
Val�rie TRICHET	Tumor-initiating and stroma-associated tumor cells within osteosarcoma, a primary bone tumor in adolescent and young adults	Inserm UMR1238 Universit� de Nantes	France
Christian VOLPO�T	Dual metabolic functions of group IV cytosolic phospholipase A2 alpha (cPLA2?) in pancreatic ductal adenocarcinoma	U1068 CRCM	France
Lo�c YSEBAERT	Computational Integration to Model Tumor Dynamics in CLL Patients Treated with the Btk Inhibitor Ibrutinib (CompuTreatCLL): First Results of an Integrative Systems Biology Approach	IUCT	France
Sonia ZAGHDOUDI	Fibroblastic FAK activity modifies PDAC microenvironment	Cancer Research Center of Toulouse (CRCT), team 6 "Protein synthesis & secretion in carcinogenesis",	France

COMPANY/TECHNOLOGY PRESENTATIONS

Invivogen



The promise of STING agonists is demonstrated by recent investments from large pharmaceutical companies. In March 2015, Novartis announced a \$750 million deal with Aduro Biotech for a STING agonist collaboration and more recently BMS acquired IFM Therapeutics with a lead STING program for \$300 million upfront. The size of these deals validates the potential of STING agonists for oncology indications in combination with immune checkpoints, and supports assessment of InvivoGen STING cyclic dinucleotides in clinical studies. We are looking to partner this program with companies and institutions that develop promising immunotherapy projects.

www.invivogen.com/

Iceram



I.Ceram has developed a porous alumina ceramic that allows the replacement of bone. Its unique capacities of bone integration, mechanical resistance and its ability to be loaded with active molecules enable using it for patients presenting osteosarcoma or bone metastases. To date, this ceramic is used for orthopedic surgery and was recently used for sternal replacement (tumor or mediastinitis). Loading was used 3 times with antibiotics (gentamicin), twice during mediastinitis and once during osteomyelitis. The first follow up of these implantations will be presented with a focus on the local delivery which confers a high local concentration associated with a very weak systemic passage. I.Ceram uses its unique industrial knowledge, know-how and trade secrets to develop alumina bio-ceramic implants capable of addressing a local treatment for bone infections and bone metastases.

www.iceram.fr/

Urosphere



Urosphere is an independent Contract Research Organization specializing in preclinical urogenital disorders. We provide the pharmaceutical and biopharmaceutical industries with an innovative experimental research platform combining both in vivo preclinical models and in vitro assays on human and animal tissues. Urosphere has recently developed a new platform dedicated to oncology. The offer includes an in vivo imaging approach of the traditional cell-line based models as well as patient-derived tumor xenograft (PDX) models. With the acquisition in 2017 of Urolead company, Urosphere/Urolead provides a unique panel of well characterized PDXs models of urological cancers (bladder, prostate, kidney).

www.urosphere.com/

Vita API



VITA API Lab developed patents on selenium (Se) enrichment in *Athrospira platensis*, and with anticancer drugs resulting in the strong potentiation of their action. In fact, several anticancer drugs (Docetaxel, Cisplatin, Oxaliplatin, Topotecan or 5-Fluorouracil) in Se-enriched *Athrospira* demonstrated in vitro potentiation in human and murine epithelial colorectal carcinoma (Caco-2 and CT26.WT) and prostate cancer (DU145) cell lines and in vivo, in nude mice xenografted with kidney adenocarcinoma cells (RCC 786-0) treated with Topotecan induced in Se-enriched *Athrospira* for 4 weeks, where tumor growth was stopped for these mice in comparison to vehicle or Se-enriched *Athrospira* treatment, and no systemic toxicity (kidney, spleen or liver) was reported. In conclusion, Se-enriched *Athrospira* as a vector for anticancer drug delivery could represent a new strategy for the development of effective and less toxic treatments against cancer.

www.proselem.eu/

Inovotion



How to use INOVOTION technology to open new perspectives for in vivo drug discovery especially for anti-cancer treatments?

Why chick embryo model has several advantages for drug discovery?

Chick embryo model fills the gap between in vitro and mouse model but is it possible to predict mouse data from chick embryo results?

www.inovotion.com

Essen Bioscience



Don't miss our talk there will be great videos of cells in action ;)

The IncuCyte® is a real-time quantitative live-cell imaging and analysis platform enabling visualization and quantification of cell behavior over time (from hours to weeks) by automatically gathering and analyzing images around the clock within a standard laboratory incubator.

The system allows to make time-lapsed fully kinetic measurements from living cells over days and weeks thus providing insight into active biological processes in real time. The IncuCyte®, with its continuous live-cell imaging and quantitative data analysis capabilities allows researchers to conduct a variety of live cell assays in a faster and automated way and is becoming an essential tool for most cell based research laboratories. We will put a special focus on Immuno-Oncology applications during this talk but the IncuCyte covers a much broader application range.

<https://www.essenbioscience.com/en/>

Pierre Fabre



After a brief introduction of the Pierre Fabre company, the presentation will be focused on Pierre Fabre capabilities and expertise in oncology. With 30 years of innovation in cancer drug development, including monoclonal antibodies, small molecules and natural cytotoxic agents, Pierre Fabre Médicament continues to expand its activities in oncology. The company has a flexible R&D model in oncology and a sustainable dynamic of agreements around the world. The Pierre Fabre pipeline in oncology, as well as the strategic focus for oncology external partnership in 2018 will be presented.

<https://www.pierre-fabre.com/>

10x Genomics



High-throughput, single-cell expression measurements enable discovery of gene expression dynamics for profiling individual cell types. the Chromium Single Cell Controller which is a dedicated instrument for single cell applications and features a simple and comprehensive workflow, enabling users to quickly and easily prepare single cell sequencing libraries in less than one workday. With the unique ability to interrogate hundreds to millions of cells. Single Cell 3' Solution for single cell transcriptomics, as well as the ability to perform full-length sequencing of paired expressed V(D)J segments from single B or T cells. The system features full compatibility with the Illumina® HiSeq® 4000 and other HiSeq®, NovaSeq®, NextSeq® and MiSeq® sequencers, and also BGI/MGI sequencing machine. During this presentation, we will highlight some published work: A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer - Cell Reports; Savage et al; 2017

<https://www.10xgenomics.com/>

Gamamabs



GM102 is a first-in-class monoclonal antibody which targets a novel tumor antigen, AMHR11. It benefits from the low-fucose EMABling® technology (license granted by LFB) which increases tumor cell killing properties through a breakthrough activation of immune system cells. In particular, GM102 activates the tumor-infiltrating macrophages, inducing a original anti-tumor activity. GM102 is in early clinical stage development, its first trial being conducted in advanced gynecological cancers

www.gamamabs.com/


Antineo



A large number of cancer patients will initially respond to medical therapy before suffering relapse with resistant disease. In order to develop novel active and original therapies it is therefore necessary to test novel agents in clinically relevant resistance models. Our models are developed from sensitive cells to be resistant to gold standard therapies, which reflect the clinical situation in which novel agents will be analyzed in the scope of phase II clinical trials. Importantly we perform molecular and phenotypic characterization of our resistance models in comparison to the parental sensitive models. Our approach provides our customers with a unique opportunity to evaluate their agents in models which are closely related to clinical situations of resistance. So far, Antineo has obtained models resistant to chemotherapy and/or immunotherapy. Those models, CDX or syngeneic, are representative of various indications.

www.antineo.fr/fr/

Miltenyi Biotec



Immuno-oncology is a rapidly growing area of translational and clinical research. Major steps forward have been made over recent years to decrypt the power of the immune system. This improved knowledge of immunological mechanism is helping researchers and clinicians in their efforts to continuously improve and advance concepts for immunotherapies in hematology/oncology. Since pioneering MACS magnetic cell separation technology in 1990, we have grown into a vibrant, multinational team of more than 1200 biomedical scientists, physicians, engineers, and support groups. Our commitment is to the advancement of biomedical research and cellular therapy. Our passion is the development of technologies that impact on basic research and clinical applications. Our customers value our reputation and years of experience in providing products that make a difference. The MACS Solutions portfolio of outstanding tools for the translation from basic research to therapy, addresses techniques of sample preparation, cell separation and analysis, molecular analysis, cell culture. From research tools to GMP reagents for sophisticated applications, such as cellular therapy and especially CAR T Cell therapy, the creativity of our interdisciplinary teams is reflected in the excellence of our products.

www.miltenyibiotec.com/

Acobiom



Acobiom is specialized in the discovery and the validation of Biomarkers for diagnostic and therapeutic purposes. The company uses its expertise for designing genomics/blood companion diagnostics. To reach its objectives, Acobiom has developed and continually refined a technology platform combining high-throughput technologies (Sequencing, NGS, RNA-Based diagnostics), and proprietary bioinformatic and data science tools, that are capable to process and analyze the generated Big Data. Acobiom has developed a high value diagnostic test based on multiple blood biomarkers and proprietary algorithms (SaaS) that predicts the response to the most common therapy in pancreatic cancer. Since the prognosis of long-term survival (OS) and the Progression Free-Survival (PFS) in pancreatic cancer are usually poor, it is essential to avoid offering ineffective treatment as soon as possible.

<https://acobiom.com/>

LGC



Recent developments of enzyme-specific or anti-angiogenesis inhibitor chemotherapies have shown limitations at clinical stages, unveiling the need for more specific, sensitive and predictive in vitro models. After enhancing the historical collection by the addition of more physiologically-relevant models and normal controls, ATCC is anticipating the future of cell biology by engineering new models to address unmet needs of the scientific community, using advanced techniques such as CRISPR-Cas9 and the human telomerase:

- Isogenic cell lines exhibiting new responses to enzyme-specific inhibitors
 - EMT reporter cell lines for live imaging of the epithelial to mesenchymal transition
 - Cancer-Associated and Normal-Associated Fibroblasts as a new tumor microenvironment tool
- ATCC's expertise in quality controls allows for the advanced characterization of these new models.

<https://www.atcc.org/>

Oncomedics



The Oncogramme® is a functional assay combining therapeutic and diagnostic approaches to predict the activity of a therapeutic molecule on a cancer patient's tumor. Chemotherapy becomes targeted using the Oncogramme®. Drugs are actually tested on a living sample of the tumor in an approach very similar to the antibiogram. Responses of the patient's own cells obtained through the Oncogramme® thus assist medical practitioners in personalizing the treatment, by favoring drugs that demonstrate a high level of anti-cancer activity while avoiding inefficient drugs.

Results obtained by Oncomedics on metastatic colorectal cancer indicate a strong increase (84% compared to 20-50% for currently employed consensus regimens) in response chances for first line treatment thanks to the Oncogramme®! Oncogramme® is a CE marked in-vitro diagnostics medical device.

www.oncomedics.com

Vect-Horus



VECT-HORUS has developed a proprietary technology platform, VECTrans®, that facilitates the targeting and delivery of imaging or therapeutic agents into the brain and tumors using receptor mediated transport. The 68Ga-LDLR peptide is a small imaging agent that targets the low-density lipoprotein receptor (LDLR) overexpressed on the surface of certain cancer-cells such as pancreatic, adrenal gland and glioblastoma cancers. Bio-distribution studies in mice implanted with tumors showed that following intravenous administration of the 68Ga-LDLR peptide, significant accumulation of the conjugate was observed in the pancreatic tumor compare to the healthy pancreatic tissue (40-fold). This technology can also be applied to radiotherapy using 177Lu-LDLR peptide. VECT-HORUS designs imaging and therapeutic agents able to diagnose, localize and deliver therapeutics directly to the site of the disease. VECTrans® is a platform that has a great potential for treating a wide range of cancers.

www.vect-horus.com

Chromalys



Radiotherapy has been widely used in cancer treatment for many years but generates significant side effects because it is very difficult to irradiate the targeted tumor without reaching the surrounding healthy tissue. This problem is exacerbated when these tumors move with the patient's breathing (liver, prostate, lungs tumors E).

Our ambition is to ensure the subjection of a radiotherapy treatment to the movements of a mobile tumor, thus greatly limiting the damages to surrounding healthy tissue. This control requires detection of tumor movements, by X-Ray radiography, simultaneously with the radiation therapy treatment. This dynamic detection will be performed by tumor labelling with our micro-reagent (called MultiLys-Tumor-Track) which will greatly help the tumor detection during radiotherapy treatment.

www.chromalys.fr/

Easychelators



EasyChelators develop innovative radiopharmaceuticals for personalized medicine. EasyChelators radiopharmaceuticals are designed for medical imaging diagnostic (PET = Positron Emission Tomography), therapy (VRT = Vectorized Radio Therapy) and Theranostic uses (2 in one Imaging and Therapy).

EasyChelators radiopharmaceuticals are built on first class, patent protected, chelators for theranostic and companion diagnostic developments.

EasyChelators pipeline is looking for Proprietary vectors for Radiopharmaceutical developments under contract and partners for Radiopharmaceutical developments under collaboration.

<https://easychelators.com>

ScreenCell



Circulating Tumor Cell (CTC), liquid biopsy of cancer, is the only tumoral material available after surgery. CTC measurement over time can provide in a real time an opportunity to better assess dynamic physiologic responses to treatment, can inform about the aggressive nature and progression of the disease, may also reveal tumor evolution under therapeutic "natural selection" and allow the identification of biologic determinants of drug resistance or progression. Because of their scarcity, one tumor cell among millions of normal hematopoietic cells, the enrichment of circulation tumor cells (CTC) is a tricky procedure associated with a risk of altering the natural state of CTC. During the last decade, several technologies have been developed on the basis of innovative principles. ScreenCell a non-invasive size exclusion technology (CE-IVD) is fast, reproducible and sensitive. It preserves CTC in their natural state, keeping them on an isolation support (IS) adaptable to the laboratory consumables and equipment. The IS facilitates handling CTC for further morphological and molecular characterization with automates and platforms, routinely used with tumor tissues of large-scale clinical trials."

www.screencell.com

Medexprim



Medexprim is an open-source software company, providing IT services for biomedical imaging research and big data projects. We alleviate the burden of extracting relevant data from PACS (Picture Archiving and Communication System) and other sources, de-identifying, cleaning and organizing data sets, while valorizing existing data.

We will present the concepts of radiomics and will present our award-winning open-source solution Radiomics Enabler®, an ETL (Extract-Transform-Load) for biomedical imaging, which we co-developed with the Toulouse University Hospitals. In a recent retrospective study, the investigator saved 96% of operator's time thanks to the solution.

<https://www.medexprim.com>

PUBLIC CONFERENCE

A conference, 3 strong themes to know
«where we are with cancer in 2018»,

Tuesday, February 6 at 6PM, Pierre Baudis Congress Center



6 FÉVRIER 2018
18H00

Centre des Congrès
Pierre Baudis

**CONFÉRENCE
GRAND PUBLIC**

**TOUS UNIS
CONTRE
le cancer**

3 THÉMATIQUES | ENTRÉE LIBRE

**Y-A-T-IL UNE PART DE HASARD
DANS LES CANCERS ?**
Professeur Gilles Favre,
Directeur du Centre de Recherches
en Cancérologie de Toulouse (CRCT),
Responsable du Collège Recherche du GIP
Institut Universitaire du Cancer de Toulouse
et Directeur du Cancéropôle Grand Sud-Ouest.

**LA PRÉVENTION
ACTIVE DU CANCER**
Dr. Cyrille Delpierre,
Directeur de recherche Inserm, Responsable de
l'équipe 5 « Cancer et maladies chroniques, inégalités
sociales de santé, accès primaire et secondaire
aux soins » de l'UMR1027 Inserm-Université Paul
Sabatier « Epidémiologie et analyses en santé
publique : risques, maladies chroniques et handicaps »

**IMMUNOTHÉRAPIES
DE NOUVEAUX TRAITEMENTS
PORTEURS D'ESPOIR**
Professeur Maha Ayyoub,
Responsable de l'équipe 1 « Immunité
antitumorale et immunothérapie » du CRCT
et Responsable de la plateforme d'immunomonitoring de l'IUCT Oncopole.

informations
www.toulouse-onco-week.org

Logos: Fondation, Toulouse, CRCT, metropole, Cancer-Bio-Santé, IUCT, QUAL.

Is there a part of chance in cancer?

Professor Gilles Favre, Director of the Cancer Research Center of Toulouse (CRCT), Head of the Research College of the GIP Toulouse University Institute of Cancer and Director of Cancéropôle Grand Sud-Ouest.

Active prevention of cancer

Dr. Cyrille Delpierre, Research Director Inserm, Team Leader 5 «Cancer and Chronic Diseases: Social Inequalities in Health, Primary and Secondary Access to Care» of UMR1027 Inserm-Paul Sabatier University «Epidemiology and Public Health Analyzes: risks, chronic diseases and disabilities»

Immunotherapies: new hopeful treatments

Professor Maha Ayyoub, Team Leader 1 «Antitumor Immunity and Immunotherapy» of the CRCT and Head of the IUCT-Oncopole Immunomonitoring Platform.

FREE ENTRY

MEDICAL SESSION

20h00-22h00 – Meeting

The regional health program about cancer

Coordination city/hospital around Diabetes

The city / hospital link around clinical cases

- Complex cases in haematology
- Prescriptions of oral targeted therapies and treatment adherence
- Side effects management and home –based immunotherapy

Best practices in city / hospital coordination

Assessment of coordination roadmaps set up in the city

INSTITUTIONAL PARTNERS



About ESOF Toulouse 2018

The biennial European event, EuroScience Open Forum (ESOF) will take place in Toulouse, «European City of Science» from 9 to 14 July 2018. «Sharing science: towards new horizons» will be the motto of this ESOF 2018 edition, a 6-in-1 event including various sections “Science”, “Science policy”, “Science to Business”, “Careers” and “Media & Science Communication” and a “Science in the City” programme dedicated to the general public. Health and its challenges, sustainable development, transport of the future, the digital world or ethics in science are some of the themes that will be tackled through conferences, exhibitions and satellite events.

www.esof.eu

Sponsors

Diamond



Silver



Bronze



Other sponsors



Media sponsor

